Navigation Links
Cepheid Receives Health Canada Medical Device License for Xpert MRSA(TM) Test and GeneXpert(R) System
Date:1/29/2008

License Enables Access to Canadian HAI Market; Market Expenditures for MRSA

Surveillance Expected to Reach $80 Million by 2012

SUNNYVALE, Calif., Jan. 29 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq: CPHD) today announced that Health Canada has issued a medical device license for the Xpert(TM) MRSA test for the rapid detection of Methicillin Resistant Staphylococcus aureus (MRSA) on nasal swabs and the GeneXpert(R) System. Xpert MRSA test results are available in approximately 70 minutes thereby enabling rapid identification of carriers of the potential pathogen in less than two hours, from the acquisition of the patient sample to returning the result to the floor. The availability of the Xpert MRSA test and the GeneXpert System is expected to help enable Canadian healthcare organizations to implement more efficient infection control measures, leading to lower hospital acquired infection rates and improved patient care.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080129/LATU101LOGO)

As is the situation in the United States, MRSA is a growing public health concern in Canada. According to a study published in the Canadian Journal of Infectious Diseases and Medical Microbiology the rate of MRSA in Canadian hospitals has increased steadily between 1995 and 2004. Patients with MRSA require prolonged hospitalization extending 26 days on average, special control measures, expensive treatments and extensive surveillance.

"There is evidence of growing worldwide concern over increasing MRSA infection rates and other Healthcare Acquired Infections such as Clostridium difficile. We expect to see more countries moving toward initiation of active surveillance programs," said Cepheid Chief Executive Officer John Bishop. "The GeneXpert System is uniquely positioned to enable organizations to provide fast, reliable MRSA test results 24 hours a day, seven d
'/>"/>

SOURCE Cepheid
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Cepheid to Present at the Piper Jaffray 19th Annual Healthcare Conference
2. Cepheid to Present at William Blair Small-Cap Growth Stock Conference
3. Cepheid Enters Agreement To Exclusively License HPV Portfolio Developed by Quantovir AB
4. Cepheid to Present at Thomas Weisel Partners Healthcare Conference
5. Cepheid Enters Into Five-Year Agreement With Northrop Grumman for the Purchase of Anthrax Test Cartridges for Use in United States Postal Service Biohazard Detection Systems
6. A Magnetic Gift: Sumter Regional Hospital Receives New MRI as Charitable Donation From Siemens
7. ImaRx Therapeutics Receives Urokinase Lot Release Approval With Extended Expiration Dating
8. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
9. Neptune Technologies receives GRAS notification in the United States
10. 012 Smile.Communications Receives License to Provide Endpoint Network Services
11. Video and Photo: Tekturna HCT(R), a Single-tablet Combination of Tekturna(R)* and a Diuretic, Receives US Approval for Treatment of High Blood Pressure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... The report “Pharmacy Automation Systems Market ... Labeling Systems, Table-top Counters) by End-user (Inpatient Pharmacy ... Trends to 2019” analyzes and studies the major ... Europe, Asia-Pacific, and the Rest of the World ... figures spread through 300 pages and in-depth TOC ...
(Date:10/20/2014)... /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today ... to $5.8 million and provides a good start to Q4.  The ... America and one in the Middle East ... record levels," said Peter Bruijns , President & CEO. "Total ... Q3 than they have been for any complete year since the ...
(Date:10/20/2014)... PLAINSBORO, N.J. (PRWEB) October 20, 2014 ... that the Sidney Kimmel Cancer Center at Thomas ... program. , Through the Strategic Alliance Partnership ... and OncLive will collaborate to raise awareness of ... cancer treatment, and other projects. Clinicians and other ...
(Date:10/19/2014)... OCTOBER 20-22, 2014: The 9th Annual ... take place at the Congress Center Basel, ... now available at http://www.abim.ch . ... from all over the globe will exchange ... products and developments on the world market. ...
Breaking Biology Technology:Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 4Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 3
... PRXL ), a leading global biopharmaceutical services,organization, ... Goldberg, M.D.,to Chief Operating Officer (COO). Dr. Goldberg ... Perceptive Informatics at,PAREXEL. He will continue to oversee ... von Rickenbach, Chairman and Chief Executive Officer of ...
... Sagent Pharmaceuticals, Inc.,a privately-held specialty pharmaceutical company, today ... USP, and cefuroxime for,injection, USP, two broad spectrum ... Sagent,s ceftriaxone for,injection will be available to the ... single,dose vials, as well as 1g and 2g ...
... PALO ALTO, Calif., July 16 Jazz,Pharmaceuticals, Inc. ... has entered,into definitive agreements with selected investors to ... of (i) one share of the Company,s,common stock, ... (ii) a,warrant to purchase 0.45 of a share ...
Cached Biology Technology:PAREXEL Promotes Dr. Mark A. Goldberg to Chief Operating Officer 2PAREXEL Promotes Dr. Mark A. Goldberg to Chief Operating Officer 3PAREXEL Promotes Dr. Mark A. Goldberg to Chief Operating Officer 4Sagent Pharmaceuticals Launches Ceftriaxone, USP, and Cefuroxime for Injection, USP 2Sagent Pharmaceuticals Launches Ceftriaxone, USP, and Cefuroxime for Injection, USP 3Jazz Pharmaceuticals Announces $26.0 Million Registered Direct Offering 2Jazz Pharmaceuticals Announces $26.0 Million Registered Direct Offering 3
(Date:10/15/2014)... As our ability to assess the pandemic risk from ... developments, we must not allow ourselves to become complacent ... an international consortium of scientists. , Influenza pandemics arise ... have yet to develop widespread immunity – spreads in ... in the past 100 years, the worst of which ...
(Date:10/15/2014)... increased resistance to bacterial pneumonia in female mice to ... , Females are naturally more resistant to respiratory infections ... shown that increased resistance to bacterial pneumonia in female ... 3 (NOS3). They also show that this enzyme is ... hormone estrogen. , The team, lead by Professor Lester ...
(Date:10/14/2014)... thieves, prostate cancer tumors scavenge and hoard copper that ... avarice may be a fatal weakness. , Researchers ... prostate cancer cells by delivering a trove of copper ... cells brimming with the mineral, leaving non-cancer cells healthy. ... commercially available for other uses, could soon be tested ...
Breaking Biology News(10 mins):Scientists 'must not become complacent' when assessing pandemic threat from flu viruses 2Prostate cancer's penchant for copper may be a fatal flaw 2
... have devised a means of identifying partial, distorted, scratched, ... seconds. Previous techniques have tried to identify a ... match them against a database of templates. The University ... each print and transform the topological pattern into a ...
... issue of G&D, Dr. Guillermo Oliver (St. ... evidence to resolve a century-old debate over the ... development of the lymphatic vasculature is integral to ... and maintaining tissue fluid levels) and disease (lymphedema ...
... Acid rain was one of the worlds worst pollution problems ... Britain, as well as Europe and North America. In ... been acidified, harming fish, stream insects and river birds such ... has been taken across Europe to clean up acid pollutants ...
Cached Biology News:New technology identifies warped fingerprints at warp speed 2Recovery from acid rain 'much slower than expected' 2
Low melting point. Ideally suited for in gel enzymatic reactions. Gelling temp. 24-28C Melting temp. 65C. EEO 0.12 Resolution 0.5-20 kb; Rnase/Dnase: none detected....
Rabbit polyclonal to XTP4 ( Abpromise for all tested applications). entrezGeneID: 84299 SwissProtID: Q9BRT3...
...
...
Biology Products: